Merja Soilu-Hänninen
MD, PhD
Turku University Hospital, Division of Clinical Neurosciences mersoi@utu.fi |
Clinical neurology; neuroimmunology; multiple sclerosis risk factors, prognostic factors and treatment
MD, University of Turku 1988
PhD, University of Turku, Department of Virology, Immunobiology of central nervous system virus infections 1996
Postdoctoral Fellow, Development and Neurobiology Group, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 1997-1999
Specialist Degree in Neurology 2001
Adjuct Professor of Clinical Neurology 2008
Inverstigator in several clinical MS trials
Chair of the Finnish MS registry 2016-
General Neurology Section Head, Turku University Hospital, Division of Clinical Neurosciences 2017-
Multiple sclerosis risk factors, prognostic factors and epidemiology.
Imaging of brain atrophy in multiple sclerosis.
Course of medical pedagogics 2011-2012
Supervisor of several PhD student
- Progressiivinen multifokaalinen leukoenkefalopatia natalitsumabihoidon komplikaationa (2013)
- Duodecim
- A randomised, double-blind, placebo-controlled trial with vitamin D3 as an add on treatment to interferon B-1b in patients with multiple sclerosis (2012)
- Journal of Neurology, Neurosurgery and Psychiatry
- A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment (2012) Åivo Julia, Lindström BM, Soilu-Hänninen M
- A randomised trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis (2012)
- Neurology
- C-reactive protein and seizures in focal epilepsy: A video-electroencephalographic study (2012)
- Epilepsia
- Multippeliskleroosi (luku 23) (2012) Patologia Matias Röyttä, Merja Soilu-Hänninen
- Parechovirus infection preceding Guillain–Barré syndrome (2012)
- Journal of NeuroVirology
- Unenaikainen kohtauksellinen tukehtumisen tunne - diagnostinen haaste (2012)
- Duodecim
- Simvastatin as add-on therapy to interferon B-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial (2011)
- Lancet Neurology
- CHARACTERIZATION OF CD4+T CELLS SPECIFIC FOR GLUTAMIC ACID DECARBOXYLASE (GAD65) AND PROINSULIN IN A PATIENT WITH EPILEPSY AND STIFF-PERSON SYNDROME, BUT WITHOUT TYPE 1 DIABETES (2010)
- Epilepsia
